RT Journal Article
SR Electronic
T1 Machine Learning Enabled Non-invasive Diagnosis of Nonalcoholic Fatty Liver Disease and Assessment of Abdominal Fat from MRI Data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.25.22272965
DO 10.1101/2022.03.25.22272965
A1 Pillai, Arvind
A1 Bliznashki, Kamen
A1 Hutchison, Emmette
A1 Kumar, Chanchal
A1 Challis, Benjamin
A1 Patel, Mishal
YR 2022
UL http://medrxiv.org/content/early/2022/03/27/2022.03.25.22272965.abstract
AB Nonalcoholic fatty liver disease (NAFLD) is the most rapidly growing contributor to chronic liver disease worldwide with high disease burden and suffers from limitations in diagnosis. Inspired by recent advances in machine learning digital diagnostics, we explored the efficacy of training a neural network to classify high risk NAFLD vs. non-NAFLD patients in the UK Biobank dataset based on proton density fat fraction (PDFF). We compared the performance of several ResNet-derived architectures in the context of whole abdomen MRI, segmented liver and abdomen excluding liver (sans-liver). Non-local ResNet trained on whole abdomen MRI images yielded the highest precision (0.88 for NAFLD) and F1 (0.89 for NAFLD). Furthermore, our work on a second, larger cohort explored multi-task learning and the relationship among PDFF, visceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue (ASAT). Interestingly, multi-task learning experiments found a decline in performance for PDFF when combined with VAT and ASAT. We address this deterioration using Multi-gate Mixture-of-Experts (MMoE) approaches. Our work opens the possibility for using a non-invasive deep learning-based diagnostic for NAFLD, and directly enables clinical and genomic research using a larger cohort of potential NAFLD patients in the UK Biobank study.Competing Interest StatementAll authors are current or past employees of AstraZeneca.Funding StatementThis study did not receive external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK BiobankI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used is the manuscript is provided by the UK Biobank to registered researchers.